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Abstract We previously reported on the serum calcium-
decreasing activity of recombinant protein factor referred to as
caldecrin [Tomomura et al. (1995) J. Biol. Chem. 270, 30315^
30321]. To address the mechanism of this serum calcium-
decreasing activity, we investigated the effect of rat caldecrin on
osteoclastic bone-resorbing activity. Wild-type caldecrin sup-
pressed resorption pit formation by osteoclast on a dentine slice
in a dose-dependent manner. The suppressive effect on the bone
resorption was not affected by treatment of caldecrin with
phenylmethyl sulfonyl fluoride or by use of protease-deficient
mutant caldecrins. Recombinant procaldecrin (313^239), and its
fragments (313^125), (1^111), (1^46), (47^111), and (126^239)
were expressed as His-tagged thioredoxin fusion proteins and
investigated for their ability to suppress bone resorption. The
proform (313^239) and fragment (313^125) did not affect the
suppressive activity, whereas fragments (1^111) and (126^239)
did suppress the bone resorption. The bone-resorbing activity was
also suppressed by fragment (47^111), not by fragment (1^46).
Overlapping fragments (47^62), (47^79), (47^98), (56^111), (71^
111), and (85^111) were compared for their suppressive activity.
The fragments (47^62) and (85^111) did not affect the activity,
but the other fragments suppressed the bone resorption. A
synthetic peptide having the (71^79) sequence suppressed the
bone resorption. These results suggest that amino acid sequence
corresponding to rat caldecrin (aa 71^79) is responsible for the
suppression of bone resorption by caldecrin. ß 2001 Federation
of European Biochemical Societies. Published by Elsevier Sci-
ence B.V. All rights reserved.
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1. Introduction
It is well known that blood calcium is regulated by a com-
plex network of calciotropic hormones, e.g. calcitonin, para-
thyroid hormone, 1K,25-(OH)2 vitamin D3, and prostaglan-
dins and cytokines [1^3]. It has been reported that acute
pancreatitis causes hypocalcemia, suggesting that the pancreas
possesses hypocalcemic factors [4]. Earlier we reported the
puri¢cation and cloning of a serum calcium-decreasing factor,
referred to as caldecrin, from porcine, rat, and human pan-
creas [5^8]. Caldecrin is a novel serine protease with a struc-
ture like that of a member of the elastase family, although
caldecrin is a chymotrypsin-type protease in terms of its ac-
tivity [7^9]. Procaldecrin, which does not possess protease or
serum calcium-decreasing activity, lowers blood calcium levels
in mice as well as protease activity upon trypsin treatment [6].
However, the protease activity of activated caldecrin is abol-
ished by treatment with the irreversible serine protease inhib-
itor, phenylmethyl sulfonyl £uoride (PMSF), but the protease
retains its serum calcium-decreasing activity [5]. Protease ac-
tivity-de¢cient mutants of recombinant caldecrin also lower
blood calcium [7].
In this paper, we report that caldecrin suppressed bone
resorption, we also examined various caldecrin fragments
for their ability to suppress such resorption.
2. Materials and methods
2.1. Animals
10-day-old white male rabbits were purchased from Japan Labora-
tory Animals Inc. (Tokyo, Japan) and were used for preparation of
unfractionated bone cells and for the bone resorption pit formation
assay.
2.2. Protein expression
Expression of recombinant wild- and mutant-type caldecrins by the
baculovirus expression system and puri¢cation were performed as
described previously [7]. Culture media of Sf9 cells transfected with
virus harboring wild-type or mutant-type caldecrin cDNAs (serine 187
mutated to alanine, or histidine 45 mutated to alanine to destroy
protease activity) were collected 72 h after transfection, concentrated,
and dialyzed against 10 mM sodium phosphate bu¡er (pH 6.8). Ex-
pressed recombinants were puri¢ed by Mono Q ion-exchange chro-
matography and dialyzed against phosphate-bu¡ered saline (PBS).
To express recombinant caldecrin fragments in Escherichia coli, we
generated histidine-tagged thioredoxin (HTRX) fusion protein expres-
sion vectors by subcloning the NdeI^BamHI fragment of pTRXFus
vector (Invitrogen) into the NdeI^BamHI site of pET16b vector (No-
vagen). Full-length caldecrin or fragments were ampli¢ed by polymer-
ase chain reaction (PCR) using the primers listed in Table 1.
Caldecrin proform (313^239) and fragments (313^125), (1^111),
(1^46), (47^111), and (126^239) were ampli¢ed by using Pfu DNA
polymerase (Stratagene), rat caldecrin cDNA as a template, and re-
spective primer pairs 1 and 8, 1 and 7, 2 and 6, 2 and 5, 3 and 6, and 4
and 8 for 30 cycles (94‡C, 30 s; 50‡C, 30 s; 72‡C, 1 min). PCR
products were cloned into the SmaI site of the expression vector.
Overlapping caldecrin fragments (47^62), (47^79), (47^98), (56^111),
(71^111), and (85^111) were ampli¢ed using caldecrin (47^111) cDNA
as a template and respective primer pairs, 9 and 10, 9 and 11, 9 and
12, 13 and 16, 14 and 16, and 15 and 16. PCR products (47^62), (47^
79) and (47^98) were digested with RsrII and BamHI, and cloned into
the RsrII^BamHI site of the expression vector. PCR products (56^
111), (71^111) and (85^111) were digested with KpnI and BamHI, and
cloned into the KpnI^BamHI site of the expression vector. All DNA
constructs were sequenced by using a BigDye Terminal Cycle Se-
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quencing kit and an ABI PRISM 310 genetic analyzer (PE Biosys-
tems). The recombinant proteins were expressed in E. coli
BL21(DE3)pLysS (Novagen) and their synthesis induced for 4 h in
M9ZB medium with 1 mM isopropyl-L-D-thiogalactopyranoside at
30‡C. Cells were harvested, solubilized in bu¡er (20 mM Tris^HCl
(pH 7.9), 0.5 M NaCl, 1 mM PMSF), sonicated ¢ve times (30 s each
time) and centrifuged at 10 000Ug for 30 min at 4‡C. The superna-
tants were applied onto a nickel-NTA-resin column. The resin was
washed with bu¡er, and bound proteins were eluted with bu¡er (20
mM Tris^HCl (pH 7.9), 0.5 M NaCl, 1 mM imidazole, 1 mM PMSF).
Recombinant proteins were dialyzed against PBS prior to use. Puri¢-
cation of recombinant proteins was evaluated by 12.5% sodium do-
decyl sulfate^polyacrylamide gel electrophoresis and Western blotting
using anti-caldecrin antibody and anti-TRX antibody (Invitrogen).
2.3. Activation of wild-type and mutant caldecrin
The puri¢ed recombinant wild-type and mutant caldecrins pro-
duced by baculovirus were activated for 30 min by trypsin at a ratio
of 1:50, and then the activation was stopped by 1 mM 4-amidinophe-
nylmethanesulfonyl £uoride. Activated caldecrin was incubated with
or without 1 mM PMSF for 10 min to abolish its activated protease
activity.
2.4. Preparation of synthetic peptides
Peptide fragments corresponding to rat caldecrin (aa 71^79;
VYAEVDTIY) and reverse peptide (YITDVEAYV) were synthesized
by Sawady Co. (Tokyo, Japan). The lyophilized peptide was dissolved
in 30% dimethylsulfoxide at a concentration of 10 mg/ml. The stock
solution was diluted with PBS and stored before use.
2.5. Culture and bone resorption pit assay
Preparation of bone cells and resorption pit formation assay were
described elsewhere [10,11]. Brie£y, unfractionated bone cells were
prepared from tibiae, femora, humeri, ulnae, and radii of 10-day-
old male rabbits. After removal of connective tissues, the long bones
were minced in 20 ml of K-MEM medium (Gibco) supplemented with
5% fetal bovine serum (FBS) (ICN). After having been separated by
vortexing for 30 s and sedimented for 2 min, unfractionated bone cells
were centrifuged for 2 min at 500Ug, and resuspended in the same
medium. The cells were seeded onto dentine slices (6 mm in diameter
and 0.07 mm in thickness) that had previously been plated with the
medium in a 96-well plate. After 2 h of incubation, the culture me-
dium was changed to fresh medium supplemented with 5% FBS and
caldecrin or caldecrin fragments; and the cells were cultured at 37‡C
in humidi¢ed 10% CO2 and 90% air. At 48 h of culture, the cells were
scraped o¡ the dentine slices, and the slices were stained with acid
hematoxylin (Sigma-Aldrich) for 6 min to visualize the excavated pit
formed by osteoclasts. Pit formation activity was expressed as a pit
area by counting the number of mesh squares covered by the pits. In
some cultures, cells were formaldehyde-¢xed and stained for tartrate-
resistant acid phosphatase (TRAP) using Sigma Diagnostics Acid
Phosphatase, Leukocyte kit (Sigma-Aldrich). Total number of
TRAP-positive multinucleated cells (MNCs) per well was determined.
3. Results and discussion
To determine whether caldecrin suppresses bone resorption
as well as lowers the serum calcium level, we performed rabbit
osteoclastic bone resorption pit formation assay. Recombi-
nant activated wild-type caldecrin suppressed the bone resorp-
tion in a dose-dependent manner, of which suppression
reached a maximum of about 50% at a 30 nM concentration
of the protease (Fig. 1A). Treatment of the activated caldecrin
with PMSF or mutation of histidine 45 or serine 187 to ala-
nine (H45A and S187A) destroyed the protease activity but
not the serum calcium-lowering activity, suggesting that the
hypocalcemic activity of caldecrin has no connection with its
protease activity [5]. Thus, caldecrins without protease activity
were compared in the bone resorption pit assay. As shown in
Fig. 1B, wild-type caldecrin inactivated by PMSF treatment
suppressed the bone resorption equally well as the activated
wild-type caldecrin. Again, activated protease activity-de¢-
cient mutant caldecrins, H45A and S187A, suppressed the
bone resorption. The number of TRAP-positive osteoclastic
MNCs was not signi¢cant between the culture with or without
caldecrin (Table 2). These results suggest that caldecrin sup-
pressed bone resorption independent of its protease activity
and cytotoxicity, and that the suppression of the bone resorp-
tion may cause the serum calcium decrease.
To determine the domain(s) of caldecrin responsible for the
suppression of osteoclastic bone-resorbing activity, we con-
structed several caldecrin fragments. The amino acid sequence
of cattle chymotrypsin C (EC 3.4.21.2) is close to that of rat
and human caldecrins. Chymotrypsin C is composed of two L-
barrel-like structures, each of which contains six to seven L-
sheets. The C-terminal barrel structure contains a short inter-
mediate helical segment and an extended C-terminal helix [12].
The positions of cysteine residues of chymotrypsin C are con-
served at the same positions in caldecrin, and the amino acids
that di¡er between chymotrypsin C and caldecrins are in the
same category of amino acids, suggesting that the three-di-
mensional structure of caldecrin may resemble that of chymo-
trypsin C. The X-ray structure of cattle chymotrypsin C dis-
Table 1
Primer sequence used for PCR
Primer no. Primer sequence (5P^3P) Starting or ending at amino acid position
1 S: 5P-TGCGGGAACCCCGCCTTCCCA-3P starting at 313
2 S: 5P-GTGGTAGGAGGAGAGGATGCT-3P starting at 1
3 S: 5P-ATCAACAAAGACTTCACTTAC-3P starting at 47
4 S: 5P-TGCTATGTCACGGGCTGGGGT-3P starting at 126
5 A: 5P-TCAGCAGTGGGCGGCAGTGAGGAC-3P ending at 46
6 A: 5P-TCAGGCCACCTGGATGGTGTTGCT-3P ending at 111
7 A: 5P-TCAGGGATAGTCCTGAGGCAGCAG-3P ending at 125
8 A: 5P-TCACAGTTGTATTTTCTCGAA-3P ending at 239
9 S: 5P-TGCGGTCCGTGCAAAATGAT-3P starting at 33 of TRX
10 A: 5P-AAGGATCCTCACAGATTATACTTCCCCA-3P ending at 62
11 A: 5P-TTGGATCCTCAGTAGATGGTGTCCACCTC-3P ending at 79
12 A: 5P-TTGGATCCTCACAACTTAATGATAGCGAT-3P ending at 98
13 S: 5P-TTGGTACCCGGCCTGGGGAAGTATAATCT-3P starting at 56
14 S: 5P-AAGGTACCCGTGTACGCTGAGGTGGACA-3P starting at 71
15 S: 5P-AAGGTACCCAACCGACTCTTCCTGTGGAA-3P starting at 85
16 A: 5P-TTGGATCCTCAGGCCACCTGGATGGTGTTGCT-3P ending at 111
S, sense primer; A, antisense primer. The stop codon is marked in bold. The restriction endonuclease site is underlined. RsrII, CGGTCCG;
BamHI, GGATCC; KpnI, GGTACC.
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plays disul¢de bonds formed between Cys (313)^Cys 112, Cys
30^Cys 46, Cys 126^Cys 193, Cys 157^Cys 173, and Cys 183^
Cys 214. Therefore, the following HTRX fused procaldecrin
and its fragments were constructed: full-length rat caldecrin
(aa 313^239), which is the proform of caldecrin; fragment (aa
313^125), which is an N-terminal barrel-like structure of the
proform; fragment (aa 1^111), which is an N-terminal part of
activated caldecrin; and fragment (126^239), which is a C-
terminal barrel-like structure (Fig. 2A).
The recombinant proteins were compared by the bone-re-
sorbing activity. As shown in Fig. 2B, HTRX did not a¡ect
the bone resorption when used as a control. HTRX caldecrin
(313^239) and HTRX caldecrin (313^125) did not a¡ect the
bone-resorbing activity. The bone resorption was suppressed
by HTRX caldecrin (1^111). The HTRX caldecrin (126^239)
also suppressed the bone resorption. Moreover, with respect
to the part of the active fragment (1^111), HTRX caldecrin
(1^46) and (47^111) were constructed and examined for their
bone-resorbing activity. The bone resorption was suppressed
by HTRX caldecrin (47^111) but not by HTRX caldecrin (1^
46). These results and the previous ¢nding that activation of
procaldecrin was required for the serum calcium-decreasing
activity [4] suggest that suppressive domain for the bone re-
sorption located in residues 47^111 requires a conformational
change caused by trypsin activation to become exposed on the
outer part of the molecule. Recently, it was reported that
human elastase IIIB displayed hypocalcemic activity and sup-
pression of bone resorption, both of which depended on its
protease activity [13^15]. Homology of the amino acid se-
quence between rat caldecrin and human elastase IIIB is
rather high (64.3%) in their C-terminal structure, compared
with (47.3%) the N-terminal structure. Thus, the suppressive
activity for the bone resorption of HTRX caldecrin (126^239)
may be similar to that of elastase IIIB. However, caldecrin
decreased serum calcium and suppressed the bone resorption
without protease activity, suggesting that the mechanism of
suppression of bone resorption by caldecrin without protease
activity is di¡erent from that for the protease activity-depen-
dent human elastase IIIB.
To address what part of the sequence was involved in sup-
pressing the bone resorption, we constructed overlapping cal-
decrin fragments HTRX caldecrin (47^62), (47^79), (47^98),
(56^111), (71^111), and (85^111) and compared their suppres-
sive activities toward bone resorption (Fig. 2C). As shown in
Fig. 2D, HTRX caldecrin (47^62) and (85^111) did not a¡ect
the suppressive activity, but the other fragments, HTRX cal-
decrin (47^79), (47^98), (56^111) and (71^111), were active in
the suppression. These results suggest that the suppressive se-
quence for bone resorption may be caldecrin residues 71^79.
The region is di¡erent from that of human elastase IIIB.
Finally, we synthesized a peptide corresponding to caldecrin
71^79 and measured its suppressive activity toward bone re-
sorption. As shown in Fig. 3, this peptide suppressed the bone
resorption in a dose-dependent manner whereas the reverse
peptide had no e¡ect, suggesting caldecrin 71^79 to be the
suppressive sequence. The region may locate in a L-sheet
structure deduced from the crystallographic results on chymo-
trypsin C [12].
The mechanism of the suppression of the bone resorption
by caldecrin 71^79 is presently unclear. This amino acid se-
quence has no homology with that of other calciotropic hor-
mones or factors. Osteoclasts are the primary cells responsible
for bone resorption and are controlled by stromal cells
through the balanced regulatory mechanism of osteoclast dif-
ferentiation factor (ODF) and osteoprotegrin, and by binding
Fig. 1. Suppression of bone resorption by recombinant rat caldecrin.
A: Dose-dependent suppression of the bone resorption by wild-type
rat caldecrin. B: Wild-type caldecrin with or without protease activ-
ity, and protease activity-de¢cient mutant caldecrins suppressed the
bone resorption. Puri¢ed recombinant rat caldecrin with or without
PMSF treatment or protease activity-de¢cient mutants (S187A,
H45A) (30 nM) were used for the bone resorption pit formation as-
say. Data are expressed as means þ S.D. values obtained from qua-
druplicates of two experiments.
Table 2
TRAP-positive MNCs in culture
Treatment TRAP-positive MNCs/well
Control 138 þ 22
Wild-type caldecrin 131 þ 13
+PMSF 134 þ 20
Mutant caldecrin
H45A 135 þ 31
S187A 132 þ 23
Data are mean þ S.D.
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of ODF to its receptor activator of nuclear factor-UB
(RANK) on the osteoclasts [16,17]. ODF is a member of
the tumor necrosis factor-related ligand family, which ligand
is composed of L-strand [16]. The L-strand in the receptor-
binding domain of vascular endothelial growth factor forms a
complex with a 20-mer receptor-blocking peptide containing a
L-strand [18]. The possibility of caldecrin interaction with
RANK or some unknown receptor or with ODF may cause
the suppression of the bone resorption. The inhibiting activity
of the peptide 71^79 to the bone resorption was less than that
of the recombinant protein (Figs. 1A and 3). It may be con-
sidered that steric factor might enhance the a⁄nity of inter-
action of caldecrin with target proteins. In any event, the
segment comprising residues 71^79 of rat caldecrin contains
the major determinant suppressing bone resorption.
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